Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy
Benzinga Newsdesk 6 hours ago
News
Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndromeThe nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome developed by
Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndrome
The nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome developed by Atrium that demonstrates key features of the disease, including cardiac glycogen accumulation, cardiac hypertrophy, and electrocardiogram (ECG) abnormalities. In the study, mice received a single dose of mATR 1072, a mouse surrogate of ATR 1072, after features of the disease had been established for three weeks. By targeting disease causing variant PRKAG2 mRNA in the heart, mATR 1072 treatment led to reversal of cardiac glycogen accumulation as well as improvement in other key features of the disease, including hypertrophy and ECG parameters.
Details of the HCMS Scientific Sessions poster:
Friday, November 6, 2026, at 5:30 p.m CT.
Targeting PRKAG2 mRNA with mATR 1072 to improve glycogen-storage cardiomyopathy in a mouse model of PRKAG2 syndrome
Presentation Number: HCM32; Poster Board Number: 32